EASTERN COOPERATIVE ONCOLOGY GROUP

约翰斯·霍普金斯自1955年以来一直是ECOG的成员。我们的初选 目标是带来创新的临床研究方案和 在约翰·霍普金斯大学进行的实验室相关研究 进一步发展。同时，我们还提供 作为礼仪研究主席的领导力，以疾病和医疗为导向 委员会主席，以及委员会在 成员级别。 是次拨款续期的具体目的是：(1) 继续提供以疾病为导向的科学领导 委员会：肺、头和颈、乳房、病理学和药理学 并将这些努力扩展到艾滋病和神经肿瘤学； 带来翻译研究、细胞生物学和分子生物学 纳入所有疾病阶段的临床方案，包括 预防；(3)扩大我们的应计项目，改善数据管理； (四)加强社区参与 医院。 我们期望通过以下成功的努力来实现这些目标 我们的教员在获得资助的实验室科学和临床 研究补助金，如肺病和前列腺癌的孢子补助金 癌症和我们与NCI签订的持续第一阶段合同。这些 赠款将允许开发I期临床试验， 包括骨髓移植、基因治疗和新技术 约翰霍普金斯大学内的细胞毒剂，然后可以被带到 针对疾病的第二阶段和第三阶段评估的ECOG。新的 约翰霍普金斯大学参与的领域包括艾滋病、淋巴瘤和神经症。 肿瘤学。机制已经到位，以带来创新研究 将这两个领域的项目纳入经社理事会。我们在学习和学习上的收益 数据管理的质量将大大提高。这将是 通过全面重组我们的数据管理来完成 办公室配备了新的行政人员，新的ECOG致力于研究 护士，以及一名新的高级数据管理协调员。应计项目是 由于扩大了临床计划和 我们计划在约翰·霍普金斯大学新建一个更大的癌症中心。 此外，社区项目的一名新主任已经 被任命的具体目标是扩大我们的医院网络 ‘为高优先级ECOG-NCI赞助商提供更多机会 包括癌症控制和预防研究在内的试验。

Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative studies piloted at Johns Hopkins to ECOG for further development. In conjunction with this, we provide leadership as protocol study chairs, disease and modality oriented committee chairs, as well as wide committee participation at the membership level. The specific aims during this grant renewal period are to: (1) continue to provide scientific leadership in the disease oriented committees: Lung, Head and Neck, Breast, Pathology and Pharmacology and to expand these efforts into AIDS and Neuro-Oncology; (2) to bring translational research, cell biology and molecular biology into clinical protocols for all stages of disease including prevention; (3) to expand our accrual and improve data management; (4) to increase participation of our affiliated community hospitals. We expect to achieve these aims through the successful efforts of our faculty in obtaining funded laboratory science and clinical research grants such as the SPORE grants in Lung and Prostate Cancer and our continuing Phase I Contract with the NCI. These grants will allow the development of phase I clinical trials, including bone marrow transplant, gene therapies, and novel cytotoxic agents, within Johns Hopkins that can then be taken to ECOG for disease-specific phase II and phase III evaluation. New areas of Johns Hopkins involvement include AIDS lymphoma and Neuro- Oncology. Mechanisms are in place to bring innovative research projects in these 2 areas into ECOG. Our accrual to studies and quality of data management will improve greatly. This will be accomplished through a total reorganization of our data management office with new administrative staff, a new ECOG dedicated research nurse, and a new senior data management coordinator. Accrual is expected to increase because of expanded clinical programs and faculty as we plan for a new larger Cancer Center at Johns Hopkins. In addition, a new director of Community Programs has been appointed with the specific goal of expanding our hospital network 'to provide greater access to high priority ECOG-NCI sponsored trials including cancer control and prevention studies.